Ibex aims to transform the pathology profession and effect a step-change in cancer diagnosis. By bringing AI and machine learning to cancer diagnosis, Ibex is driving a new era in the practice of pathology – offering greater speed, consistent accuracy and significant cost-savings for the health industry.
The company’s partnership with Israel HMO Maccabi allows access to the world’s best clinical dataset for pathology – 2 million patient records, 5 million pathology slides and 2.5 million pathology reports, together with 15+ years of full medical history. These underpin Ibex’s proprietary algorithms.
The product is fully developed for both prostate and breast tissue analysis, and is the first of its kind ever deployed in a clinical setting.
Ibex raised its Series A from aMoon, 83 North, Dell Technologies and AXA.
Offices: Tel Aviv
Investment: Series A